Clinical trials: Opioid-induced Constipation (OIC)
Therapeutic Opioid Induced Constipation (Disorder)
Use of MgSO4 for Pain After Bariatric Surgery
The purpose of this study was to investigate the effect of magnesium sulfate on pain management for pain after sleeve gastrectomy operation
- Trial name
- NCT03355807
- Testing
- Magnesium
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Yeditepe University Hospital
Neoplasms, Constipation
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease.
- Conditions
- Neoplasms, Constipation, Opioid-Related Disorders
- Trial name
- NCT01004393
- Testing
- Methylnaltrexone bromide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Vermont
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901328
- Testing
- CB-5945
- Volunteers
- 49 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Opioid Induced Constipation
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.
- Trial name
- NCT03060512
- Testing
- Polyethylene Glycol 3350, Movantik
- Where
- 53 sites in United States
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
OIC
ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
The purpose of this study is to evaluate the safety and efficacy of ALKS 37 when administered daily to adults with OIC.
- Trial name
- NCT01418092
- Testing
- ALKS 37
- Where
- 13 sites in United States
- Volunteers
- 91 people
- Sponsor
- Alkermes, Inc.
Opioid Induced Constipation
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation
- Trial name
- NCT01401985
- Testing
- TD-1211
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Glycyx Therapeutics
Constipation
Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.
- Trial name
- NCT00366431
- Testing
- MOA-728
- Where
- 67 sites in United States
- Volunteers
- 420 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid Induced Constipation
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
This is a single-arm, open label, multinational, multicentre, prospective, real world observational study of Naloxegol in adult subjects with Opioid Induced Constipation (OIC) in patients receiving Naloxegol in routine clinical…
- Trial name
- NACASY (NCT03638440)
- Testing
- Naloxegol
- Where
- 10 sites in Denmark, Finland and 8 more
- Volunteers
- 183 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Constipation, Cancer
Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients
This is a study to compare the efficacy and tolerability of two laxatives for treatment of opioid-induced constipation in adult outpatients with cancer treated at the British Columbia Cancer Pain and Symptom Management/Palliative…
- Trial name
- NCT01189409
- Testing
- PEG then Senna, Senna then PEG
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- British Columbia Cancer Agency
Constipation
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).
- Trial name
- NCT00529087
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 78 sites in United States
- Volunteers
- 460 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid-induced Constipation
Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
The purpose of this study is to examine the safety and activity of MNTX in relieving opioid-induced constipation following orthopedic procedures.
- Trial name
- NCT00640146
- Testing
- Methylnaltrexone bromide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid Induced Constipation
Naloxegol Drug Utilization Post Authorisation Safety Study
This post-authorization observational safety study determines the characteristics of patients prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in follow-up in the United Kingdom (UK), Norway…
- Trial name
- NCT02813148
- Testing
- Naloxegol
- Where
- 4 sites in Germany, Norway and 2 more
- Volunteers
- 17,254 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Opioid-Induced Constipation
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness.
- Trial name
- NCT00672477
- Testing
- Methylnaltrexone
- Where
- 60 sites in United States, Australia and 10 more
- Volunteers
- 237 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Severe Pain
A Non-interventional, Observational Study for Targinact® Treatment in Patients With Chronic Severe Pain
This non-interventional, observational study is set up on request of the Belgian reimbursement authorities and evaluates the efficacy of Targinact with regard to pain relief and constipation in daily clinical practice in Belgium…
- Trial name
- NCT01710904
- Testing
- Targinact® (oxycodone/naloxone)
- Where
- Belgium
- Volunteers
- 68 people
- Sponsor
- Mundipharma CVA
Opioid Induced Constipation
A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).
The main purpose of this study is to assess how effective and tolerable the country specific clinical practice guidelines of SLTs are for UK, France and Sweden are.
- Trial name
- NCT01957046
- Testing
- Laxative
- Where
- Sweden
- Volunteers
- 117 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Opioid Induced Constipation
Naloxegol US PMR CV Safety.
The overall research goal for this study is to provide additional data to characterize the safety of naloxegol in patients aged 18 years and older who do not have a diagnosis of cancer and who are treated with opioids chronically
- Trial name
- NCT02813356
- Testing
- naloxegol, non-PAMORA
- Where
- 2 sites in United States
- Volunteers
- 8,800 people
- Sponsor
- Valinor Pharma LLC
Constipation
Naloxegol in Cancer Opioid-Induced Constipation
The purpose of this study is to compare the effect of naloxegol versus the patient's usual care in treating opioid-induced constipation, as well as the effect on the patient's quality of life and how much pain is experienced.
- Trial name
- NCT02745353
- Testing
- naloxegol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Joseph Ma
Opioid-Induced Constipation (OIC)
Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
The purpose of this study is to evaluate the long-term safety and tolerability of NKTR-118 treatment of opioid-induced constipation (OIC) in patients with non-cancer-related pain.
- Trial name
- NCT01336205
- Testing
- NKTR-118, Usual care
- Where
- 169 sites in United States
- Volunteers
- 844 people
- Sponsor
- AstraZeneca
Opioid-Induced Bowel Dysfunction
Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone
The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with Opioid-induced Bowel Dysfunction.
- Trial name
- OPAL (NCT00595946)
- Testing
- Lubiprostone
- Where
- 95 sites in United States, Canada
- Volunteers
- 439 people
- Sponsor
- Sucampo Pharma Americas, LLC
Opioid-Induced Constipation
Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
This purpose of this study is to evaluate the safety and effectiveness of a subcutaneous (injection beneath the skin) form of methylnaltrexone in subjects who have cancer-related pain and constipation from taking opioids.
- Trial name
- NCT00858754
- Testing
- methylnaltrexone
- Where
- 8 sites in United States, Canada and 2 more
- Sponsor
- Bausch Health Americas, Inc.